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Abstract
Background: Pax3 is a key upstream regulator of the onset of myogenesis, controlling progenitor cell survival and
behaviour as well as entry into the myogenic programme. It functions in the dermomyotome of the somite from
which skeletal muscle derives and in progenitor cell populations that migrate from the somite such as those of the
limbs. Few Pax3 target genes have been identified. Identifying genes that lie genetically downstream of Pax3 is
therefore an important endeavour in elucidating the myogenic gene regulatory network.
Results: We have undertaken a screen in the mouse embryo which employs a Pax3
GFP allele that permits isolation
of Pax3 expressing cells by flow cytometry and a Pax3
PAX3-FKHR allele that encodes PAX3-FKHR in which the DNA
binding domain of Pax3 is fused to the strong transcriptional activation domain of FKHR. This constitutes a gain of
function allele that rescues the Pax3 mutant phenotype. Microarray comparisons were carried out between Pax3
GFP/
+ and Pax3
GFP/PAX3-FKHR preparations from the hypaxial dermomyotome of somites at E9.5 and forelimb buds at
E10.5. A further transcriptome comparison between Pax3-GFP positive and negative cells identified sequences
specific to myogenic progenitors in the forelimb buds. Potential Pax3 targets, based on changes in transcript levels
on the gain of function genetic background, were validated by analysis on loss or partial loss of function Pax3
mutant backgrounds. Sequences that are up- or down-regulated in the presence of PAX3-FKHR are classified as
somite only, somite and limb or limb only. The latter should not contain sequences from Pax3 positive neural crest
cells which do not invade the limbs. Verification by whole mount in situ hybridisation distinguishes myogenic
markers. Presentation of potential Pax3 target genes focuses on signalling pathways and on transcriptional
regulation.
Conclusions: Pax3 orchestrates many of the signalling pathways implicated in the activation or repression of
myogenesis by regulating effectors and also, notably, inhibitors of these pathways. Important transcriptional
regulators of myogenesis are candidate Pax3 targets. Myogenic determination genes, such as Myf5 are controlled
positively, whereas the effect of Pax3 on genes encoding inhibitors of myogenesis provides a potential brake on
differentiation. In the progenitor cell population, Pax7 and also Hdac5 which is a potential repressor of Foxc2, are
subject to positive control by Pax3.
Background
During embryonic development, the Pax family of tran-
scription factors play important roles in cell type specifi-
cation and organogenesis [1]. In vertebrates, Pax3 is a
key upstream regulator of skeletal myogenesis. This
paired-box homeo-domain transcription factor is present
in myogenic progenitor cells of the developing muscle
masses and also in the multipotent cells of the somites
from which all skeletal muscles in the trunk and limbs
derive. Somites form as segments of paraxial mesoderm
following a rostral/caudal gradient on either side of the
embryonic axis. Initially Pax3 is expressed throughout
the epithelial somite and then becomes restricted to the
dorsal domain, the dermomyotome, which maintains an
epithelial structure. The ventral somite gives rise to
bone and cartilage of the vertebral column and ribs,
whereas the Pax3 positive cells of the dermomyotome
* Correspondence: margaret.buckingham@pasteur.fr
† Contributed equally
6CNRS URA 2578, Département de Biologie du Développement, Institut
Pasteur, 25 Rue du Dr Roux, 75015 Paris, France
Full list of author information is available at the end of the article
Lagha et al. BMC Genomics 2010, 11:696
http://www.biomedcentral.com/1471-2164/11/696
© 2010 Lagha et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.give rise to other mesodermal derivatives, including
derm, smooth muscle and endothelial cells, as well as
skeletal muscle. Experiments in the chick embryo [2-4]
and in the mouse [5] have shown that different cell
types derive from a single Pax3 positive cell. Myogenic
progenitors delaminate from the edges of the dermo-
myotome to form the underlying skeletal muscle of the
myotome. As development proceeds, the central domain
o ft h ed e r m o m y o t o m ew h e r eP a x 7 ,t h ep a r a l o g u eo f
Pax3, is also expressed, loses its epithelial structure and
these Pax positive cells enter the underlying muscle
masses where they constitute a progenitor cell popula-
tion for all subsequent muscle growth. In the absence of
both Pax3 and Pax7, these cells fail to enter the myo-
genic programme and many of them die [6]. The hypax-
ial domain of the dermomyotome, where Pax3, but not
Pax7, is mainly expressed in the mouse, is an important
source of myogenic progenitors. At the level of the limb
buds, cells migrate from this domain to form the skele-
tal muscle masses of the limb. In the absence of Pax3,
these cells fail to delaminate and migrate and subse-
quently undergo cell death [1]. Pax3 therefore controls
migration of myogenic progenitor cells from the somite,
entry into the myogenic programme and survival.
In order to understand how Pax3 functions in the
multipotent cells of the dermomyotome and subse-
quently in myogenic progenitors, it is necessary to char-
acterize Pax3 targets. During myogenesis in vivo very
few targets have been identified. Notably, c-Met has
been proposed as a direct Pax3 target [7]. This gene
encodes a tyrosine kinase receptor that interacts with
HGF, required for the delamination, and probably also
the migration, and proliferation of myogenic progenitors
[8]. Pax3 activation of the c-Met promoter, although not
fully demonstrated in vivo,p r o v i d e sa ne x p l a n a t i o nf o r
the absence of progenitor cell migration and limb myo-
genesis in Pax3 mutants. This is also consistent with
rescue of the ectopic migration seen in Pax3
PAX3-FKHR/+
embryos, when c-Met is absent [9]. Entry of Pax3/7
positive progenitor cells into the myogenic programme
depends on the myogenic determination factors, Myf5
and MyoD. Analysis of regulatory sequences in the 5’
flanking region of Myf5, led to the characterization of
an element at -57.5 kb from the gene that is responsible
for transcription in the limb buds and older hypaxial
somite. Activation of this element depends directly on
Pax3 [10]. The MyoD gene is also regulated by a Pax3/7
binding site [11], although this regulation has not been
explored in an embryonic context. Pax7 has a more lim-
ited expression pattern than Pax3 in the mouse somite,
h o w e v e rt h e yp r o b a b l ys h a r em a n yo ft h es a m et a r g e t s ,
as indicated by the embryonic phenotype of a Pax3
Pax7/
Pax7 mouse line in which Pax7 replaces Pax3 [12].
Further Pax3/7 targets have been identified using the C2
muscle cell line in which Pax3 or Pax7 was over-expressed
[13,14]. In this context the Myf5 regulatory sequence tar-
geted by Pax3 in the embryo was also shown to be a Pax7
target. Id3, which encodes a potential inhibitor of basic-
helix-loop-helix transcription factors such as Myf5 or
MyoD, was identified as a direct Pax3 target [14]. In the
context of human Rhabdomyosarcomas, which result from
a chromosomal translocation leading to the expression of
a fusion protein, PAX3-FKHR or PAX7-FKHR in which
the PAX DNA binding domain is followed by the strong
transcriptional activation domain of the FOXO1A (FKHR)
factor, a number of microarray screens have been per-
formed on cultured cells (for review see [15]). Examples
are provided by cDNA two colour arrays in which the
authors identified genes differentially regulated by PAX3
or PAX3-FKHR over-expression in NIH3T3 cells [16], by
Affymetrix arrays to find genes induced by PAX3 expres-
sion in a human medulloblastoma cell line [17], or by a
casting approach of cyclic amplification and selection of
cis-regulatory elements bound by human PAX3, PAX3-
FKHR or murine Pax3 [18]. Very few target genes were
common to these three approaches, probably reflecting
the artificial conditions of the screens.
More recently, we have initiated a screen to systemati-
cally look for Pax3 targets in the mouse embryo. Since
myogenic progenitors tend to die in the absence of
Pax3, complicating the interpretation of a screen based
on a comparison with material from Pax3 mutants, we
used a gain of function approach. This was based on a
Pax3
PAX3-FKHR-IRESnlacZ/+ (Pax3
PAX3-FKHR/+) line that we
had made, in which Pax3 targets such as c-Met,a r e
over-activated. Pax3
PAX3-FKHR thus constitutes a Pax3
gain of function allele. We had previously shown that in
Pax3
PAX3-FKHR/Splotch embryos (where Splotch is a spon-
taneously occurring Pax3 mutant allele) the Pax3
mutant phenotype is not observed, indicating that
PAX3-FKHR can replace Pax3, which thus acts as a
transcriptional activator in the myogenic context [9].
A Pax3
GFP/+ m o u s el i n e[ 6 ]p e r m i t t e di s o l a t i o no f
Pax3-GFP progenitor cells by flow cytometry, so that
the transcriptomes of purified populations of Pax3
GFP/+
versus Pax3
PAX3-FKHR/GFP c e l l sc o u l db ec o m p a r e db y
microarray analysis. This screen led to the identification
of Sprouty1 and Fgfr4 shown to be a direct Pax3 target,
and the demonstration that the self-renewal, versus
entry into the myogenic programme, of myogenic pro-
genitors is partly orchestrated by Pax3 modulation of
FGF signalling [19]. Dmrt2, was also identified as a
direct Pax3 target. This gene encodes a transcription
factor, present in the Pax3 positive cells of the dermo-
mytome, which regulates an early epaxial enhancer ele-
ment of the Myf5 gene, required for the onset of
myogenesis in the somite [20]. This screen also revealed
that Foxc2 is negatively controlled by Pax3,a n dt h a t
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somite and subsequently in the dermomyotome where
these genes are co-expressed. Modulation of this equili-
brium affects cell fate choices, resulting in Pax3 positive
myogenic progenitors or Foxc2 positive vascular pro-
genitors [21].
In this paper, we provide the first documentation of
the in vivo gain of function screen for Pax3 targets and
present data on other interesting candidates.
Results and Discussion
Experimental strategy and microarray results
Our strategy depended on the purification of Pax3 positive
cells, which was implemented using a mouse line
(Pax3
GFP/+) in which one allele of Pax3 had been targeted
with a GFP coding sequence [6], so that cells expressing
this allele could be isolated by flow cytometry. This line
was crossed onto the conditional Pax3
PAX3-FKHR-IRESnlacZ/+
(Pax3
PAX3-FKHR/+) line [9] to produce Pax3
PAX3-FKHR/GFP
embryos. After a further cross with a PGK-Cre transgenic
line [22], this resulted in a Pax3 gain of function genetic
background. In the crosses used here, Pax3
PAX3-FKHR/GFP
embryos had a similar phenotype to Pax3
PAX3-FKHR/+
embryos. From our previous analysis of the Pax3
PAX3-FKHR/+
line [9], we know that PAX3-FKHR can save the Pax3
mutant phenotype, thus substituting for Pax3. This is
accompanied by over-activation of known Pax3 targets such
as c-Met, leading to some myogenic abnormalities. We used
this allele to generate a gain of function genetic background.
Somites in the interlimb region of E9.5 Pax3
GFP/+
(Figure 1A) and Pax3
PAX3-FKHR/GFP (Figure 1B) embryos
were dissected to obtain the dorsal epithelial structure of
the dermomyotome, which was cut away from the epaxial
domain adjacent to the neural tube. This corresponds to a
stage when most myogenic progenitors are still present in
the dermomyotome, with cells delaminating from the epax-
ial dermomyotome to form the early skeletal muscle of the
myotome. Care was taken to avoid Pax3 positive cells in the
dorsal neural tube, although the presence of migrating
neural crest cells from this source, that also express Pax3
[1], could not be excluded. Forelimb buds were dissected
from Pax3
GFP/+(Figure 1C) and Pax3
PAX3-FKHR/GFP (Figure
1D) embryos at E10.5, when Pax3 positive cells had
migrated from the hypaxial domain of adjacent somites, but
h a dn o ty e tf o r m e dd i f f e r e n t i a t e ds k e l e t a lm u s c l ei nt h ef o r e -
limb buds. In this case, neural crest should be absent, since
these cells do not enter the limb buds. After dissection, cells
were dissociated from pooled samples of somites or forelimb
buds from Pax3
GFP/+ and Pax3
PAX3-FKHR/GFP embryos
and separated by flow cytometry to obtain GFP positive
fractions for microarray analysis (Figure 1E). In addition to
the comparison of GFP+ cells from Pax3
PAX3-FKHR/GFP;
Pax3
GFP/+embryos, GFP+/GFP- populations were compared
from Pax3
GFP/+ embryos to identify sequences specific to
Pax3 positive myogenic progenitors (Figure 1F). Obtaining
enough material is a challenge at these embryonic stages,
particularly from the forelimb bud which contains about
1000 Pax3 positive cells at E10.5, so that it was necessary to
prepare material from >100 embryos with each genetic back-
ground in order to have enough material for cDNA synth-
esis, sample verification (see Additional file 1 Figure S1) and
triplicate Affymetrix chip analyses.
Raw data were pre-processed to obtain expression
values using the RMA (Robust Multichip Analysis)
algorithm. Unreliable probe-sets called “absent” by Affy-
metrix Gene Chip Operating Software (GCOS) software
(http://www.affymetrix.com/support/downloads/
manuals/data_analysis_fundamentals_manual.pdf
website) for at least 2 GeneChips out of 3 were dis-
carded. LPE (Local Pooled Error) tests [23] were
performed to identify significant differences in gene
Figure 1 Strategy of the screen for Pax3 targets. (A-D) Embryos
viewed under a fluorescence microscope from Pax3
GFP/+ (A, C) and
Pax3
PAX3-FKHR/GFP (B, D) mouse lines at E9.5, focussing on the
interlimb somites (A, C) and at E10.5 focussing on the forelimb bud
(B, D). Dotted lines indicate the region dissected. (E) Isolation of GFP
positive cells by flow cytometry from the two genotypes indicated,
shown for material from E10.5 forelimb buds. The region R3,
outlined in E, was used for transcriptome analysis of GFP positive
cells. GFP negative cells were obtained from the R4 window shown
in (E). (F) Microarrays were performed on RNA isolated from cells of
interlimb somites and forelimb buds (A-D) with the genotypes
indicated. The comparisons gave information about sequences that
mark Pax3 positive myogenic progenitors (1) and that are candidate
Pax3 targets (2).
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PAX3-FKHR/GFP; Pax3
GFP/+ and
GFP+; GFP- samples. Benjamini-Hochberg (BH) [24]
multiple-test correction was applied to control for
the number of false positives with an adjusted 5%
statistical significance threshold.
These data are available on the http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE22041 website.
Comparisons for E9.5 dermomyotome and E10.5 fore-
limb bud preparations are presented in Additional file 2
Tables S1-S3. Genes that are up-regulated (A) or down-
regulated (B) in both somites and limb buds are shown in
Additional file 2 Table S1. Additional file 2 Table S2
shows genes up-regulated (A) or down-regulated (B) for
forelimb buds only, whereas Additional file 2 Table S3A
and B shows such genes in somites only. Transcripts
absent from the Pax3-GFP positive population, but
observed in the presence of PAX3-FKHR are not included,
s i n c et h e ym a yb ed u et on o n - P A X 3d e p e n d e n tF K H R
activity. Transcripts that are present in Pax3-GFP positive
cells and not detectable in the presence of PAX3-FKHR
were retained. Pax3 transcripts are in this category and
indeed provide a control, since the mouse gene is not tran-
scribed in Pax3
PAX3-FKHR/GFP embryos. The additional
microarray screen, in which the transcriptome of the GFP
negative cell population was compared to that of the
Pax3-GFP positive population, gives an overview of tran-
scripts that characterise myogenic progenitor cells of the
forelimb bud, as shown in Additional file 3 Table S4.
Neural crest markers, such as AP2 gamma (Tcfap2c) or
Ascl1 (also named Mash1) are present in the E9.5 dermo-
myotome lists and are also seen to a minor extent in the
E10.5 limb samples, probably indicating the presence of
some somitic material. This is also suggested by the pre-
sence of markers of differentiating muscle, such as skele-
tal muscle myosin or troponin, expressed at this stage in
the myotome of the somite. The presence of markers of
the sclerotome, such as Pax1 [25], probably reflects the
inclusion of cells from the ventral somite compartment,
perhaps due to some perduration of GFP, since the
Pax3
GFP allele is expressed throughout the epithelial
somite [21]. A gene encoding another typical marker of
the sclerotome compartment, Uncx4.1 [26], was present
in the list of Pax3 targets (Additional file 2 Table S1A),
and also, unexpectedly, in the list of GFP+ specific genes
for the limb bud (Additional file 3 Table S4). This may
suggest that it is also expressed in myogenic progenitors,
and indeed, the expression of Uncx4.1 is compromised in
the absence of Pax3 (data not shown).
Experimental validation of sequences of potential Pax3
targets modulated by PAX3-FKHR
Genes that showed differences in expression on the PAX3-
FKHR gain of function genetic background were validated
by qRT-PCR on a Pax3 loss of function background. In
order to avoid the problem of loss of cells due to cell
death in the mutant, the same number of Pax3-GFP
positive cells from Pax3
GFP/+ and Pax3
GFP/nlacZ embryos
were analysed, after purification by flow cytometry (Figure
2A). Examples are shown in Figure 2B, for somites at
E10.5. This is an important control to confirm that the
increase in transcripts seen in the presence of PAX3-
FKHR is not due to an effect of the fusion protein, other
than that of strong transcriptional activation via Pax3
binding sites. Another control is provided by whole mount
in situ hybridisation on different genetic backgrounds,
which also demonstrates the localisation of cells that
express the gene. In this case, the partial loss of function
Pax3
Pax3-En-IRESnlacZ/+ (Pax3
Pax3-En/+) line [10] was used,
which expresses a fusion protein, with the Pax3 DNA
binding domains fused to the repression domain of
Engrailed. This results in down-regulation of Pax3 targets
with the advantage that there is less cell death, as shown
by X-gal staining, although migration of progenitor cells
to the forelimb bud is compromised. This is illustrated for
Tbx3 transcripts on Pax3 gain (Figure 2C, D) and partial
loss (Figure 2E, F) of function backgrounds. Tbx3 is also
expressed in cardiac neural crest [27], however its
expression profile in the somites points to activation in a
subdomain of this paraxial mesoderm. Further examples
of PCR based analysis of the distribution of Pax3 targets,
is shown in Additional file 1 Figure S1. Comparison of
Sox2 and Sox10 transcripts in Pax3 positive cells of dif-
ferent somite preparations indicates that these are high
in samples that include the neural tube, consistent with
expression in neural crest (Additional file 1 Figure S1B).
Comparison of expression in the whole somite (Addi-
tional file 1 Figure S1A), with the hypaxial domain is
also informative, indicating, for example, that Zic1 tran-
scripts are enriched in the whole somite, consistent with
an expression mainly in the epaxial domain [28], as seen
by immunofluorescence on sections (Additional file 1
Figure S1C), where Zic1 protein is co-expressed with
Pax3 in the epaxial dermomyotome as well as in the dor-
sal neural tube and in Pax3 negative mesenchyme. Pax3
positive neural crest does not appear to express Zic1, in
accordance with a recent report on its absence in migra-
tory neural crest cells in the chick embryo [28]. In situ
hybridization on sections confirms expression of Zic1 in
the epaxial domain of the epithelial dermomyotome
(Additional file 1 Figure S1E). Up-regulation of Zic1 tran-
scripts in somites of Pax3
GFP/GFP embryos in the epaxial/
central domain, which is less affected by cell death, is
consistent with negative regulation by Pax3 (Additional
file 2 Table S2B).
Cell survival and malignancy
In the absence of Pax3, myogenic progenitor cells
undergo apoptosis. This phenotype, in addition to data
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Page 4 of 17Figure 2 Examples of validation on Pax3 loss of function genetic backgrounds. Genes that emerged from the microarray analyses as
potential Pax3 targets from the gain of function screen were checked on Pax3 loss of function genetic backgrounds. (A-B) Quantitative PCR
analysis of transcripts in Pax3-GFP cells separated by flow cytometry (FACS) from interlimb somites of Pax3
GFP/+ and Pax3
GFP/nlacZ embryos at
E10.5 (A). The same number of cells were analysed for each genotype and the results for Gremlin1, Mbnl3, Timp3 and Vg113 transcripts are
presented as histograms relative to the Pax3
GFP/+ sample taken as 1 (B). In accordance with the microarray data, these genes are positively
regulated by Pax3. (C-F) Whole mount in situ hybridization with a Tbx3 probe on control (C, E), Pax3
PAX3-FKHR/+ gain of function (D) and Pax3
Pax3-
En/+ partial loss of function (F) embryos at E10.5, showing somites in the interlimb region. Tbx3 transcripts are high in the hypaxial somite
domain, notably in more anterior somites, and their level depends positively on Pax3, as indicated by the microarray data. In the forelimb buds,
there is extensive expression of Tbx3 in posterior mesenchyme which masks transcripts in Pax3 positive myogenic progenitors. In the lower
panels, X-gal staining of b-galactosidase from nlacZ (C’,E ’)( Pax3
nlacZ/+)o rIRES-nlacZ (Pax3
PAX3-FKHR-IresnlacZ/+ in D’, Pax3
Pax3-En-IresnlacZ/+ in F’)
reporters shows the extent of the somites, notably the hypaxial domain which undergoes cell death in Pax3 mutants (F’).
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cated in cell survival [29]. Our list of Pax3 target genes
is not obviously enriched in such genes; however sec-
ondary modifications of cell survival proteins are not
detected in this approach. Very few genes associated
with carcinogenesis emerge as PAX3-FKHR targets. This
is in contrast to screens performed in Rhabdomyosar-
coma cell lines (for review, see [15]). This may be
explained by the physiological level of expression of
PAX3-FKHR, similar to that of Pax3 in our screen as
well as the in vivo context; Pax3
PAX3-FKHR/+ mice do not
develop tumours unless a second mutation affecting a
tumour suppressor occurs [30]. In Rhabdomyosarcoma,
a chromosomal translocation has taken place, potentially
affecting genome regulation, and the cells examined are
derived from an adult tumour, so that the context is dif-
ferent from that of embryonic cells expressing a Pax3-
PAX3-FKHR allele.
In this report we concentrate on signalling pathways
and transcription factors implicated in myogenesis.
Pax3 modulation of signalling pathways
In Table 1 examples of genes encoding components of
signalling pathways that are up- (red) or down- (blue)
regulated in the presence of PAX3-FKHR in limbs and/
or somites are shown. A number of major signalling
pathways lie genetically downstream of Pax3.I ns o m e
cases, such as FGF or Eph pathways, transcripts for both
ligands and receptors are present in Pax3-GFP positive
cells, indicative of autocrine signalling, which is subject
to Pax3 regulation.
Transcripts of the enzyme, Sulfatase1, that sulfates
extracellular matrix Proteoglycans positively affecting
the binding/stability and availability of ligands such as
FGF, Wnts and Shh, are up-regulated in the presence of
PAX3-FKHR. This is a potentially important level at
which signalling, and consequent cell behaviour, is
modulated. Indeed in a comparison of quiescent versus
in vivo activated Pax3 positive muscle satellite cells,
expression of genes such as Sulfatase1, affecting extra-
cellular matrix interaction with growth factors, was
strikingly modified [31]. In addition to effectors of sig-
nalling pathways, inhibitors depend on Pax3 activity. In
some cases, due to feedback regulation, activation of a
gene for an inhibitor, may reflect activation of a path-
way, however it may also demonstrate an important
potential for Pax3 modulation of the outcome of signal-
ling, depending on the myogenic context.
Pathways subject to Pax3 regulation include receptor
tyrosine kinase (RTK) pathways, such as FGF, as well as
Shh and Wnt signalling which promote myogenesis.
Most effectors of RTK signalling pathways are positively
regulated by Pax3. Unless specified, regulation is not
necessarily direct.
FGF signalling is strikingly affected by Pax3 and Fgfr4
has now been shown to be a direct target [19]. Pax3 reg-
ulation of Sprouty1, encoding an intracellular inhibitor
of RTK signalling, has consequences for myogenic pro-
genitor self-renewal, versus entry into the myogenic pro-
gramme, promoted by this pathway in the embryo [19].
More recently, Sprouty1 has been implicated in control-
ling quiescence of adult satellite cells [32], although it is
not notably modulated in vivo in comparisons with acti-
vated satellite cells [31]. We investigated Sprouty1
mutant embryos [33], in which a LacZ reporter per-
mitted clearer identification of Sprouty1 expressing cells.
In the mutants, expression of the myogenic regulatory
genes, Myf5 or MyoD, viewed by whole mount in situ
hybridization appears normal (Additional file 1 Figure
S2 A-D) and Desmin, which marks muscle cells, is
expressed in the myotome as expected (data not
shown). However Sprouty2 and Sprouty4 are also
expressed in somites [34] (Additional file 1 Figure S2E-
F) and may therefore compensate for the absence of
Sprouty1. Pax3 regulates multiple components of the
FGF signalling cascade, from the ligand/receptor to
transcriptional effectors, such as the Ets transcription
factors (Etv1, Etv2).
Other RTK pathways, such as IGF and PDGF, also
promote myogenesis (for ex [35]); Igf1 and Pdgfc are up-
regulated in the presence of PAX3-FKHR. The c-Met
gene was one of the first Pax3 targets to be proposed in
a myogenic context [7]. In our screen, transcripts for
this gene are up-regulated in somites (Additional file 2
Table S2, [9]), but not limb buds (Additional file 2
Table S3), suggesting that Pax3 activation of transcrip-
tion is confined to the somite (see also Additional file 1
Figure S1), where c-Met is required for delamination
[36], although the transcripts (Additional file 3 Table
S4) continue to be present in cells that migrate to the
limb buds.
A number of genes for Ephrin ligands (EphrinA5,
EphrinB1) and receptors (EphA7, EphA3) are regulated
by Pax3 in both somites and limbs, suggesting expres-
sion in myogenic cells, as well as neural crest [37].
Recently, up-regulation of Eph receptors and ligands has
been reported in several Rhabdomyosarcoma cell lines
(EphB: [38] EphA [39]). In a myogenic context in vivo,
Eph receptors have been implicated in muscle pattern-
ing and inervation [40,41]. The EphA signalling pathway
may also interfere with FGF/MAPK signalling [42,43].
The notochord and ventral neural tube are sources of
Shh signalling. In a myogenic context this impacts the
adjacent epaxial dermomyotome where Zic1, for exam-
ple, is highly expressed (Additional file 1 Figure S1), and
where Shh is implicated in the activation of Myf5 [44]
as well as in promoting cell survival and proliferation in
the somite [45]. Canonical Wnt signalling, from the
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and Myf5 activation [46], with a potential relay through
non-canonical Wnts, such as Wnt11 [47]. Components
of these pathways are modulated positively or negatively
i nt h ep r e s e n c eo fP A X 3 - F K H Rs u g g e s t i n gt h a tP a x 3
fine-tunes Wnt and Shh signalling, probably also limit-
ing the spatial extent of their action in the somite (see
Additional file 1 Figure S1 for Zic1).
Other signalling pathways, such as Notch, that, like
FGF, affect self-renewal/differentiation [48,49] show
some modulation by Pax3. This is also the case for sig-
nalling through Integrins, where the laminin gene
encoding the ligand, Lama2, is up-regulated (Table 1),
also seen for Lama1 via Dmrt2, which is a Pax3 target
[20], whereas transcripts for the Integrin receptors,
Itgb6 and Itgb8, are down-regulated (Table 1). Integrins,
some of which lie genetically downstream of Myf5,a r e
important for the structure and myogenic regulation of
the dermomyotome and for the formation of the basal
lamina that contains the myotome [50].
Transcripts for a number of cytokines and their recep-
tors are present in Pax3 positive cells. Some show mod-
ulation by Pax3, although this did not include CXCR4,
regulated by Lbx1, and important for the migration of a
subpopulation of myogenic progenitors into the limb
bud [51].
BMP/TGFb signalling, from the dorsal neural tube
and lateral mesoderm, has been shown to antagonise
the onset of myogenesis [52]. Again, Pax3 affects this
signalling pathway, notably by positively regulating
genes encoding both ligands and inhibitors such as
Chordin-like1, Follistatin and Gremlin1. In the chick
embryo, manipulation of Noggin, produced in the
somite, had shown the importance of this inhibitor in
permitting MyoD activation and the onset of myogenesis
[53]. Gremlin1 is expressed at the extremities of the
Table 1 Changes in transcripts for genes implicated in major signalling pathways between Pax3-GFP/+ samples from
somites and/or limbs of gain of function Pax3PAX3-FKHR/GFP and control Pax3GFP/+ embryos: UP (bold), DOWN
(italics)
Pax3
PAX3-FKHR/GFP vs Pax3
GFP/+
RTK FGF Ligands/Extracellular matrix FGF5, FGF12, Sulfatase1
Receptors Fgfr4, Fgfr3
Intracellular components Dusp4, Fap
Inhibitors Spry1, Spry4, Ing5, Spred1
Transcriptional components Etv1, Etv2
IGF Ligand Igf1
PDGF Ligand Pdgfc
Effector (target) Csrp1 (Axud1)
Met Receptor c-Met
Eph Ligands EphrinA5, EphrinB1
Receptors EphA7, EphA3
Shh Ligands/Extracellular matrix Sulfatase1
Inhibitors Hhip
Transcriptional components Zic1
Wnt Ligands/Extracellular matrix Wnt16, Sulfatase1
Intracellular components Siah2, Diversin (Ankrd6)
Inhibitors Sfrp3 (Frzb1), Dkk1, Dkk2, Diversin, Wif1, Csrp1 (Axud1)
Transcriptional components TCF15, TCF7/2 , Nkd2
Integrins Ligands Lama2
Intracellular components Itgb1bp2
Receptors Itgb6, Itgb8
Cytokines Ligands CXC15, CXC12, Cxcl14, Cxcl5
Intracellular components CXCR7, Crlf1
Inhibitors Soc3
Notch Ligands Dll1, Dll3
Inhibitors Fhl1 (Kyot2)
Transcriptional components Hes1
TGFb/BMP Ligands BMP5, TGFb2, TGFbinduced, Thbs1
Inhibitors Chordin-like1, Follistatin, Gremlin
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Page 7 of 17dermomyotome at E9.5 (Additional file 2 Table S3A) and
subsequently declines in the epaxial domain of more
mature somites (Additional file 1 Figure S1B, C) to be no
longer detectable by E11.5. It is up-regulated in the pre-
sence of PAX3-FKHR (Additional file 3 Figure S3A)
(Additional file 1 Figure S3 D, E). In Gremlin1 mutant
embryos [54], Pax3 expression is normal (results not
shown). Somitic expression of Myf5 (Additional file 1
Figure S3F, G) and MyoD (Figure S3 H, I) is also similar
to wild type or heterozygote embryos. However, there is
some delay in the onset of expression in the hypaxial
domain. There is also a delay in MyoD expression in the
forelimb bud at E11.5 (Additional file 1 Figure S3),
probably reflecting perturbations in signalling pathways
within the limb [54]. The lack of a more striking pheno-
type may reflect compensation by other BMP inhibitors,
such as Noggin.
A striking finding of this screen is the variety of genes
for inhibitors of signalling pathways that are controlled
by Pax3. These include Sprouty1, Sfrp3, Gremlin1 and
Hhip, which encode inhibitors of FGF, Wnt, BMP and
Shh signalling, respectively (Table 1). This indicates that
Pax3 negatively modulates the activity of signalling path-
ways as well as promoting their activation. The role of
the FGF inhibitor, Sprouty, in maintaining the myogenic
stem cell population in the face of FGF signalling that
promotes entry into the myogenic differentiation pro-
gramme has been demonstrated [19]. In addition, path-
ways that negatively impact entry into the myogenic
programme, such as BMP/TGFb, are also abrogated by
inhibitors, as illustrated for Gremlin, precisely expressed
at the extremities of the dermomyotome where activa-
tion of myogenic determination factors is first initiated.
Pax3 modulation of genes implicated in transcription
Examples of genes involved in the control of transcrip-
tion that show up- or down-regulation in Pax3 positive
(Pax3-GFP) cells in the presence of PAX3-FKHR, com-
p a r e dt oc o n t r o l s ,a r ep r e s e n t e di nT a b l e2 ,3 ,4 .T h i si s
divided into three sections for differentially regulated
genes in both somites (E9.5) and forelimbs (E10.5)
(Table 2) or only in forelimbs (Table 3) or only in somites
(Table 4). Transcriptional effectors of signalling pathway
(see Table 1) have been removed from Table 2, 3, 4.
Pitx genes, such as Pitx2, which is positively regulated by
Pax3, have been implicated in myogenesis [55]. Very few
Pitx target genes have been identified to date. Recently, in
zebrafish, a member of the Shroom family, encoding an
actin binding protein implicated in epithelial organization
[56,57], has been reported to be a direct target of Pitx fac-
tors [58]. Interestingly, Shroom2, like Pitx2, is up-regulatd
by Pax3 in the somite (Additional file 2 Table S2). The
Pax3-Pitx2-Shroom2 cascade may be implicated in the
maintenance of the epithelial organization of the hypaxial
dermomyotome in the mouse embryo.
Lbx1 is another gene that is implicated in myogenesis
(Table 4). Previous observations on decreased Lbx1
expression in Pax3 mutants were difficult to interpret
Table 2 Changes in transcripts for transcription factors
common to somites and forelimbs between Pax3-GFP/+
samples from gain of function Pax3PAX3-FKHR/GFP and
control Pax3GFP/+ embryos: UP (bold), DOWN (italics),
FC (fold change)
Gene Title Gene
Symbol
FC
limb
FC
somite
vestigial like 3 (Vito2) Vgll3 8.41 2.22
developing brain homeobox 1 Dbx1 6.38 5.19
transcription factor AP-2, gamma Tcfap2c 4.45 1.53
transcription elongation regulator 1-
like
Tcerg1l 3.61 2.21
Unc4.1 homeobox Uncx4.1 3.36 1.66
PR domain containing 8 Prdm8 3.05 1.93
T-box 3 Tbx3 2.30 2.16
paired box gene 7 Pax7 2.12 1.54
histone deacetylase 5 Hdac5 1.97 1.58
myogenic factor 5 Myf5 1.90 1.85
nescient helix loop helix 2 Nhlh2 -2.06 -0.59
brachyury T -2.17 -0.55
homeo box A4 Hoxa4 -2.64 -1.95
forkhead box C2 Foxc2 -3.17 -1.47
homeo box B1 Hoxb1 -4.49 -2.33
paired box gene 3 Pax3 -4.91 -1.73
Table 3 Changes in transcripts for transcription factors
from forelimbs only between Pax3-GFP/+ samples from
gain of function Pax3PAX3-FKHR/GFP and control
Pax3GFP/+ embryos: UP (bold), DOWN (italics), FC (fold
change)
Gene Title Gene
Symbol
FC
limb
ladybird homeobox 1 homolog corepressor 1 Lbxcor1 3.58
nuclear receptor subfamily 3, group C,
member 1
Nr3c1 2.91
distal-less homeobox 5 Dlx5 2.81
myocardin Myocd 2.64
jumonji domain containing 1C Jmjd1c 2.58
runt related transcription factor 1 Runx1 2.27
tet oncogene 1 Tet1 2.20
H6 homeo box 3 (Nkx5-1) Hmx3 2.00
homeo box A9 Hoxa9 -1.82
homeo box A10 Hoxa10 -2.01
nuclear receptor subfamily 0, group B,
member 1
Nr0b1 -2.50
single-minded homolog 2 Sim2 -3.16
SRY-box containing gene 2 Sox2 -4.04
zinc finger protein of the cerebellum 1 Zic1 -4.45
forkhead box G1 Foxg1 -11.40
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Page 8 of 17because of cell death in the hypaxial somite, where the
gene is expressed at limb levels [1], however the gain of
function result shown here indicates that Pax3 lies
genetically upstream of Lbx1. This result was confirmed
by whole mount in situ hybridization on Pax3
Pax3-En/+
partial loss of function embryos at E9.5 (Figure 3B),
when apoptosis due to perturbation of Pax3 function is
minimal [10] as shown by X-gal staining of Pax3 expres-
sing cells (Figure 3D). Lbx1 is also expressed in cells
migrating to the limbs, but was not modified in the
limb bud microarrays suggesting that, like c-Met (which
appears as a potential Pax3 target in the dermomyotome
but not in the limb), this aspect of its expression is not
Pax3 dependent. This result suggests that Pax3 regulates
the expression of Lbx1 and c-Met to control cell delami-
nation from the hypaxial dermomyotome of the somite,
but not later during progenitor cell migration to the
limb buds, thus dissociating its function in delamination
Table 4 Changes in transcripts for transcription factors from somites only between Pax3-GFP/+ samples from gain of
function Pax3PAX3-FKHR/GFP and control Pax3GFP/+ embryos: UP (bold), DOWN (italics), FC (fold change)
Gene Title Gene Symbol FC somites
paired-like homeodomain transcription factor 2 Pitx2 3.00
ladybird homeobox homolog 1 Lbx1 2.67
trans-acting transcription factor 5 Sp5 2.55
zinc finger protein 568 Zfp568 2.46
inhibitor of DNA binding 4 Id4 2.39
fos-like antigen 2 Fosl2 2.34
Kruppel-like factor 4 Klf4 2.28
nuclear receptor subfamily 4, group A, member 3 Nr4a3 2.26
doublesex and mab-3 related transcription factor like family A2 Dmrta2 1.86
inhibitor of DNA binding 2 Id2 1.82
ISL1 transcription factor, LIM/homeodomain Isl1 1.75
Kruppel-like factor 11 Klf11 1.60
inhibitor of DNA binding 1 Id1 1.57
zinc finger, CCHC domain containing 12 Zcchc12 1.55
zinc finger, MYND domain containing 11 Zmynd11 1.54
LIM homeobox protein 2 Lhx2 1.54
transcription factor AP-2 beta Tcfap2b 1.50
basonuclin 2 Bnc2 1.45
doublesex and mab-3 related transcription factor 2 Dmrt2 1.45
mohawk homeobox Mkx 1.43
histone cluster 2, H3c1 Hist2h3c1 -1.42
nuclear receptor co-repressor 2 Ncor2 -1.43
forkhead box C1 Foxc1 -1.45
runt-related transcription factor 1; translocated to 1 Runx1t1 -1.46
homeo box C8 Hoxc8 -1.47
zinc finger and BTB domain containing 16 Zbtb16 -1.47
similar to COUP-TFI/nuclear receptor subfamily 2, group F, member 1 Nr2f1 -1.47
T-box 22 Tbx22 -1.47
homeo box C5 Hoxc5 -1.51
homeo box C6 Hoxc6 -1.51
myocyte enhancer factor 2C Mef2c -1.52
basic helix-loop-helix family, member e22 Bhlhe22 -1.55
achaete-scute complex homolog 1 (Drosophila) Ascl1 -1.56
single-minded homolog 1 (Drosophila) Sim1 -1.58
Meis homeobox 1 Meis1 -1.58
dachshund 1 (Drosophila) Dach1 -1.72
chromodomain helicase DNA binding protein 8 Chd8 -2.04
myogenic factor 6 Myf6 -2.26
myogenin Myog -2.35
paired-like homeobox 2b Phox2b -2.39
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Page 9 of 17and migration. In Pax3 positive cells in the forelimb
bud, Lbxcor1, which encodes a co-repressor of Lbx [59]
is up-regulated (Table 3), suggesting that by this stage
repression of Lbx activity is important. In the limbs, the
gene for the cytokine receptor, CXCR4, that is required
for the development of a subset of myogenic cells,
depends on Lbx1 [51]in vivo.R e s u l t sin vitro show that
expression of CXCR4 is regulated by PAX3-FKHR in
Rhabdomyosarcoma cell lines [60] and by Pax7 in
C2C12 cell lines [13]. However the level of CXCR4 tran-
scripts is not altered in the presence of PAX3-FKHR in
our screen in the embryo, although they are present in
Pax3-GFP positive cells, as expected (Additional file 3
Table S4).
Six homeo-domain transcription factors, with their
Eya co-activators and Dach co-repressors, are also
important upstream regulators of myogenesis [1]. Tran-
scripts for these factors are present in the Pax3-GFP
positive cells (Additional file 3 Table S4), but only
Dach1 expression is affected by PAX3-FKHR (Table 4);
it is down-regulated, in keeping with Pax3 promotion of
Six myogenic activity. Manipulation of Dach, which is
high in quiescent satellite cells, demonstrates its nega-
tive role in activated Pax3-GFP positive cells, retarding
their entry into myogenesis [31].
Sim1 and Sim2 transcripts, that mark hypaxial somite
domains and migrating myogenic progenitors [61,62],
are both negatively regulated by PAX3-FKHR. Sim2 has
been shown to prevent epithelial/mesenchymal transi-
tions (EMT) through repression of Slug [63]. When
PAX3-FKHR is transfected into NIH3T3 cells, Slug tran-
scripts are up-regulated [16]. Pax3 repression of Sim2
may be necessary to promote delamination of migratory
myogenic cells and indeed in Pax3
PAX3-FKHR/+ embryos
there is premature EMT, accompanied by up-regulation
of c-Met [9]. Experiments in the chick embryo have
shown that FGF signalling from the myotome triggers
the expression of Snail, a known regulator of EMT [64].
In our transcriptome data, neither Snail nor Slug
expression was affected and therefore EMT in this con-
text may involve other transcriptional regulators.
Many Hox genes (Hoxa4, a9, a10, Hoxb1 and Hoxc5,
c6, c8), present in somites and/or limbs, are down-
regulated in Pax3-GFP positive cells in the presence of
PAX3-FKHR. This is an intriguing finding. Hox gene
regulation at the level of the somites, with consequences
for myogenesis, has already been documented [65,66].
Our findings now suggest a reciprocal relationship.
Foxc2, is negatively regulated by PAX3-FKHR [21]
(Table 2) and this is also the case to a lesser extent for
Foxc1 in somites (Table 4). Reciprocal negative regula-
tion between Pax3 and Foxc2 has been implicated in
cell fate choices of multipotent cells in the dermomyo-
tome, such that high Pax3 promotes myogenesis at the
expense of vasculogenesis and vice versa [21]. Runx1,
a n dt h er e l a t e dg e n eRunx1t1, are up-regulated in the
presence of PAX3-FKHR in forelimb buds and somites
respectively (Table 2, 3, 4). Runx1 is a factor that marks
endothelial cells, some of which, in the limb, derive
from the dermomyotome [2]. This would suggest that
Pax3 may contribute to the priming of cells to become
endothelial, although it is Foxc2 that promotes the
Figure 3 Lbx1 expression depends on Pax3. (A, B, E, F) Whole
mount in situ hybridisation with an Lbx1 probe of control (A, E),
Pax3
Pax3-En/+ partial loss of function (B) and Pax3
PAX3-FKHR/+ gain of
function embryos (F) at E9.25 (A, B) and E10.5 (E, F), showing down-
regulation of Lbx1 transcripts when Pax3 activity is reduced, and
some up-regulation of its expression in the presence of PAX3-FKHR
in somites. In the lower panels (C, D) X-gal staining of b-
galactosidase from the IresnlacZ reporter in Pax3
IresnlacZ/+ (C) or
Pax3
Pax3-En-IresnlacZ/+ (D) shows the extent of the somites, notably the
hypaxial domain.
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Page 10 of 17vascular fate. Myocardin is also up-regulated, indicating
positive control by Pax3 (directly or indirectly). Myocar-
din controls smooth muscle differentiation [67] and this
may also be indicative of such “priming”. However some
smooth muscle markers are also expressed in differen-
tiating skeletal muscle cells in the embryo. Unexpected
expression of Myocardin in the dorsal somite had
already been reported [67].
T h eg e n et h a te n c o d e st h em y o g e n i cd e t e r m i n a t i o n
factor, Myf5, is up-regulated by PAX3-FKHR, both in
the somite at E9.5 and in E10.5 forelimb buds (Table 2).
This is consistent with direct activation by Pax3 of the
Myf5 limb regulatory element [10] and of regulation of
early Myf5 expression through Dmrt2, which is itself a
Pax3 target in the dermomyotome in the epaxial and
potentially also the hypaxial domain [20] (Table 4).
Interestingly the gene for the transcriptional co-factor
Vgll3 (also called Vito-2) is up-regulated (Table 2 see
also Figure 2B). Vgll3, expressed at the onset of myo-
genesis [68], enhances the transcriptional activity of TEF
transcription factors that bind to MCAT motifs, present
in many skeletal muscle specific genes [69]. In this con-
text, Six homeodomain proteins, in addition to their
upstream role in concertation with Pax3 at the onset of
myogenesis, also, unlike Pax3, directly activate differen-
tiation genes. Down-regulation of the gene for the Six
co-repressor, Dach1 will also promote differentiation.
However genes encoding transcription factors associated
with myogenic differentiation, such as Myogenin, Mrf4,
Mef2c and downstream muscle genes, such as Myosins
or Troponins are down-regulated in the presence of
PAX3-FKHR (Additional file 2 Table S3B). Activation of
myogenic differentiation may be prevented by negative
regulation in Pax3 expressing cells of Meis1 (Table 4),
which encodes a protein, required for chromatin accessi-
bility in a myogenic context, as shown for MyoD [70].
Mbnl3 (Muscleblind-like 3), up-regulated by PAX3-
FKHR (Additional file 2 Table S3A, Figure 2B), encodes
a protein that inhibits MyoD dependent gene expres-
sion, thus antagonising differentiation [71]. In this con-
text, Myocardin in concertation with Hdac5, also
modulated by Pax3 (see below), represses MyoD/Myf5
activation of the Myogenin promoter [72], thus prevent-
ing skeletal muscle differentiation. Myocardin expres-
sion, also detected in the dermomyotome [72], may
prevent premature differentiation of Myf5 expressing
cells in the hypaxial domain. Furthermore differentiation
will be reduced by the positive effect of Pax3 on the
expression of Id1, Id2 and Id4 (Table 4), encoding helix-
loop-helix proteins which complex with basic helix-
loop-helix factors such as MyoD, interfering with DNA
binding [73]. Id3 did not emerge from our screen, but
this gene had been identified as a Pax3 target in cul-
tured muscle cells [14]. Overexpression of Pax7 in
cultured muscle cells identified Id2,a sw e l la sId3,a sa
target [13]. In the embryo, targeting of Pax3 alleles with
a Pax7 coding sequence [12] showed that Pax7 can
replace Pax3 and therefore that these genes share com-
mon targets. These observations indicate that while
Pax3 is required for entry into the myogenic pro-
gramme, it also acts as a brake on muscle differentiation
and indeed continued high level of expression of Pax3
retards the onset of differentiation in muscle satellite
cells [74].
Transcripts of Pax7, the paralogue of Pax3, are higher
in the presence of PAX3-FKHR in both limbs and
somites (Table 2). Down-regulation of Pax7 in somites,
when Pax3 activity is reduced, is seen by whole mount
in situ hybridization with a Pax7 probe on Pax3
Pax3-En/+
embryos (Figure 4B). When quantitative PCR is per-
formed on RNA isolated from the same numbers of
Pax3-GFP cells purified by flow cytometry from
Pax3
GFP/+ and Pax3
GFP/nlacZ embryos, the reduction of
Pax7 transcripts in the absence of Pax3 is striking (Fig-
ure 4C, D). This observation on Pax3 dependence of
Pax7 expression is important in understanding Pax3/7
regulation of muscle stem cell fate. This in vivo result is
in contrast to in vitro observations where PAX3-FKHR
overexpression in human Rhabdomyosarcoma cell lines
leads to a down-regulation of PAX7 expression [60]. It
has also been reported that Pax7 is up-regulated in the
somites of Pax3 mutant (Splotch) embryos [75], however
this was not a quantitative analysis, and somite disorga-
nisation in the absence of Pax3 complicates the inter-
pretation of in situ hybridisation.
Finally, the gene encoding the histone deacetylase,
Hdac5, a class II histone deacetylase, that acts as a nega-
tive regulator of transcription, is up-regulated in Pax3-
GFP positive cells in the presence of PAX3-FKHR in
somites and limb buds (Table 2). Expression of Hdac5
at these sites of myogenesis is shown by whole mount
in situ hybridization in Figure 5A and confirmation that
it is positively regulated by Pax3 is shown by qRT-PCR
on RNA from the same number of Pax3-GFP positive
cells (Figure 5B). Pax3 acts mainly as a transcriptional
activator in the myogenic context [9] and therefore
genes that are down-regulated in a Pax3 gain of func-
tion context are probably indirectly regulated by Pax3.
Foxc2 is an example of such a gene [21]. Hdac5 is a can-
didate negative intermediary. In Hdac5 mutants, Foxc2
is up-regulated (Figure 5D), indicating that Pax3 repres-
sion of Foxc2 may be mediated by Hdac5, which is itself
positively regulated by Pax3.
Conclusions
We have identified sequences that are potential Pax3
targets, thus giving insight into Pax3 orchestration of
progenitor cell behaviour prior to, and at the onset of,
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including inhibitors as well as activators, emerge from
the screen, demonstrating how Pax3 modulates their
impact on progenitor cell behaviour and progression
towards muscle. This is also evident from transcriptome
analysis of chromatin remodelling and transcription fac-
tors/co-factors. Pax3 regulated sequences modulate
initial cell fate decisions in the multipotent Pax3 positive
stem cells of the dermomyotome. In this case Hdac5,
positively regulated by Pax3, negatively impacts Foxc2
expression. Foxc1 is also down-regulated indirectly by
Pax3. In this stem cell context, Pax3 positively regulates
Pax7 also implicated in reciprocal repression with
Foxc1/c2 [21]. Entry into the myogenic programme is
promoted by down-regulation by Pax3 o ft h eg e n ef o r
the Six1/4 co-repressor Dach2 and also by the
previously demonstrated activation of the myogenic
determination gene Myf5, which in this case has been
shown to be direct [10]. Genes for myogenic differentia-
tion factors and downstream muscle proteins are mainly
down-regulated by Pax3, acting negatively on the gene
for the chromatin remodelling factor Meis and positively
on the Id gene family of myogenic inhibitors as well as
on Myocardin. Pax3, either directly or indirectly, is thus
acting as a brake on muscle differentiation, while prim-
ing entry into the myogenic programme. Regulation of
myogenic progenitor cell behaviour, both at the level of
signalling pathways and of transcriptional control, is
modulated by balanced up- and down-regulation of
genes that lie genetically downstream of Pax3.
Methods
Mouse lines
The following mouse lines were used: Pax3
GFP/+, Pax3-
PAX3-FKHR-IRESnlaZ/+ (referred to as Pax3
PAX3-FKHR/+),
Pax3
Pax3-En-IRESnlacZ/+ (referred to as Pax3
Pax3-En/+),
Pax3
nLacZ/+,H d a c 5
nlacZ/+, Sprouty1
lacZ/+, Gremlin1
+/-
and the PGK-Cre transgenic line. Embryos were geno-
typed as described previously: Pax3
GFP/+ [6,10], Pax3-
PAX3-FKHR and Pax3
nLacZ [9], Pax3
Pax3-En [10], PGK-Cre
Figure 4 Pax7 expression depends on Pax3. (A, B) Whole mount
in situ hybridisation with a Pax7 probe of wild-type (WT) (A) and
Pax3
Pax3-En/+ partial loss of function (B) embryos at E10.5, showing
down-regulation of Pax7 transcripts when Pax3 activity is reduced.
(C) GFP positive cells were isolated by flow cytometry (see Figure 2)
from the interlimb somites of Pax3
GFP/+ and Pax3
GFP/nlacZ embryos at
E10.5. The same number of cells in each case was used for RNA
preparation and quantitative PCR analysis, with Pax7 and Gapdh
primers; mRNA levels are shown relative to Gapdh transcripts with
the heterozygote control level taken as 1. Histograms represent
mean fold change for four different biological samples analyzed in
duplicate at each stage; error bars, standard error to the mean
(SEM); **p < 0.005.
Figure 5 The Hdac5 gene is positively regulated by Pax3 and
negatively affects Foxc2. (A) Whole mount in situ hybridisation at
E10.5 with an Hdac5 probe. Arrows point to expression at sites of
myogenesis in the somites and forelimb bud. (B) GFP positive cells
were isolated by flow cytometry (see Figure 2) from interlimb
somites of Pax3
GFP/+ and Pax3
GFP/nlacZ embryos and the same
numbers of cells were used for RNA preparation and quantitative
PCR analysis of Hdac5 and Gapdh transcripts; mRNA levels are
shown relative to Gapdh transcripts with the heterozygote control
(Pax3
GFP/+) level taken as 1. Histograms represent mean fold change
for two different biological samples analyzed in duplicate at each
stage; error bars, standard error to the mean (SEM). (C-D) Whole
mount in situ hybridisation with a Foxc2 probe on Hdac5
+/- (C) and
Hdac5
-/- (D) embryos at E9.5, showing up-regulation of Foxc2 in
somites in the absence of Hdac5.
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nlacZ/+ [76], Sprouty1
lacZ/+ [33], Gremlin1
+/-
[54]. The targeted Pax3 lines used in this analysis have
been bred for many generations on a C57 BL6/DBA2
genetic background.
For the screen, Pax3
GFP/+ mice were crossed with
PGK-Cre transgenic mice to obtain Pax3
GFP/+; PGK-Cre
females. These females were crossed with Pax3
PAX3-
FKHR-IRESnlacZ/+ males to obtain embryos with one
Pax3
GFP allele and one floxed Pax3
PAX3-FKHR-IRESnlacZ
allele [9].
Preparation of embryonic material for in situ gene
expression and micro-array analysis
Embryos were collected after natural overnight mating
and dated, taking Embryonic day (E) 0.5 as the day after
the appearance of the vaginal plug. Briefly, embryos
were fixed in 4% para-formaldehyde at 4°C, overnight
for in situ hybridization, 2 hours for immuno-detection
and 15 minutes for X-Gal staining.
Embryos were dissected in DMEM medium. For tissue
preparation from E9.5 embryos, somites were dissected
from the interlimb region and the more hypaxial domain
separated from the neural tube and epaxial extremity of
the somites. An effort was made to take the epithelial der-
momyotome, viewed by Pax3-GFP fluorescence under the
microscope. The forelimb buds at E10.5 were separated
from the adjacent somites under a fluorescence micro-
scope. Only 1000 cells were collected per limb bud from a
Pax3
GFP/+ embryo, so that a total of 490 embryos were
dissected, 125 of which were Pax3
PAX3-FKHR/GFP and 107
were Pax3
GFP/+. The genotype was revealed by GFP
fluorescence and characteristic head and neural tube
abnormalities in Pax3
PAX3-FKHR/GFP embryos [9], as well as
by b-galactosidase activity shown by X-gal staining of the
rest of the embryo (from the Pax3
PAX3-FKHR allele). The
limb buds and hypaxial somites were pooled according to
their genotype and then dissociated by passage through a
2 ml syringe and filtered before the flow cytometry sorting.
Triplicate samples of each population were prepared,
representing a starting material of a minimum of
100,000 cells per sample. GFP+ cells were separated by
flow cytometry using a MoFlo cell sorter (Beckman-
Coulter USA). The gates for positive and negative GFP
cells were determined using an equivalent sample iso-
lated from wild type embryos. Analysis was done with
the Summit software version 3.4.
RNA isolation and microarray analysis
Total RNA was extracted and purified after DNase 1
(Amersham) treatment using the RNeasy Mikro kit
(Qiagen). RNA and cRNA quality was monitored on
Agilent RNA Pico LabChips (Agilent). cRNA obtained
from 100 ng of RNA was amplified by using the Gene-
Chip Expression Two-Cycle 3’amplification system
(Affymetrix). Fragmented biotin-labeled cRNA samples
were hybridized on GeneChip Mouse Genome 430_2
arrays, according to the manufacturer’s protocol (http://
www.affymetrix.com/support/downloads/manuals/
expression analysis technical manual.pdf). The Affyme-
trix 430.2.0 mouse array that contains 45,000 probe sets
was used. Each probe set consists of 22 probes of 25 bp,
with 11 perfect matches and 11 mismatches. For each
experimental group (Pax3
+/+, Pax3
GFP/+ and Pax3
PAX3-
FKHR/GFP), three biological replicates were hybridized.
The generation of cell intensity files and the quality con-
trol of hybridizations were performed with GeneChip
Operating Software (Affymetrix).
Statistical analysis of microarray data
Statistical analyses of data were performed as described
previously [31].
Raw data were pre-processed using the Robust Multi-
chip Analysis (RMA) algorithm in order to correct the
background, to adjust the intensity distribution over the
arrays and to convert probe intensity summarisation
into a unique probe set signal. Unreliable probe-sets
called “absent” by Affymetrix GCOS software for at least
2 GeneChip out of 3 were discarded. Local Pooled Error
(LPE) tests [23] were performed in order to identify sig-
nificant differences in gene expression between Pax3-
GFP positive cells from Pax3
PAX3-FKHR/GFP and Pax3
GFP/
+ embryos on the one hand and between GFP+ and
GFP- samples from Pax3
GFP/+ embryos on the other
hand. The Benjamini-Hochberg (BH) multiple correc-
tion test [24] was applied to control for the number of
false positive with an adjusted 5% statistical significance
threshold. The fold changes of the differentially
expressed genes after p-value adjustement were analyzed
by filtering the data set with a threshold of 1.5 (Log2
ratio = 0.5). Significantly regulated genes in Pax3
PAX3-
FKHR/GFP samples, that are common to both limb and
somite extracts, are represented in Additional file 2
Table S1. Transcripts that are specifically up- or down-
regulated in the limb or in the trunk, respectively, are
referred to as “somite only” in Additional file 2 Table S2
and “limb only” in Additional file 2 Table S3.
Genes that are specifically transcribed in the GFP
positive fraction (absent in GFP negative fraction) are
represented in Additional file 3 Table S4, again as com-
mon to somites and limbs (A), somite specific sequences
(B) and limb specific sequences (C).
Accession Numbers
The complete microarray data have been deposited in
NCBI’s Gene Expression Omnibus and are accessible
through GEO series accession number GSE22041
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE22041).
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Whole-mount in situ hybridizations with digoxigenin-
labeled probes were performed as described in [77]. In
situ hybridization for Pax7 transcripts was carried out
as described in [12] and for transcripts of Foxc2 as
described in [21]. The Tbx3 p r o b ew a sa sd e s c r i b e di n
[27]. The Zic1 probe was synthesized using the image
clone Image 4314316 (Open Biosystems) and linearised
by EcoR1 and transcribed using T3 polymerase. The
mouse Grem1 cDNA (containing the complete coding
region and 3-UTR) was isolated by RT-PCR from cDNA
of RNA prepared from C57BL/6 mouse embryos at
E9.5. The Grem1 cDNA was subcloned into pBS
digested with EcoRl and BamHl and transcribed using
T3 polymerase for in situ hybridization.
When needed, the whole-mount stained embryos were
embedded into gelatin-sucrose, frozen and sectioned, as
described in [19].
Quantitative and semi-quantitative real-time PCR
RNA was extracted from embryonic material (interlimb
somites) and reverse transcribed using SuperScript II kit
(Invitrogen) for qRT-PCR and SuperscriptIII kit for semi-
quantitative RT-PCR. All PCR reactions were carried out in
duplicate (triplicate for the standard curves) using the
Power Sybergreen Mix (Applied Biosystems) and a 7500
thermal cycler (Applied Biosystems). All qPCR results are
expressed as relative ratios of the target cDNA to Gapdh
transcripts normalized to that ratio in the reference condi-
tion, which always corresponds to heterozygote Pax3
GFP/+
embryos. Primers used for detecting specific transcripts
were designed with Primer3 (see Additional file 4 Table S5).
Immunofluorescence
Fluorescent co-immunohistochemistry on sections was
carried out as described previously [19]. The following
antibodies were used: anti-Zic1 (Abcam, ab7524-25),
1/500; anti-Pax3 (DSHB), 1/250. Images were acquired
with Apotome Zeiss and Axiovision 4.6 software at the
Pasteur imaging center (Imagopole, Institut Pasteur).
Mouse work was carried out in accordance with the
regulations of the French Ministry of Agriculture, as
practised by the Ministry accredited mouse animal house
of the Pasteur Institute under the supervision of scientists
and technicians with the official authorisation to experi-
ment on mice. The authors have paid attention to the
ARRIVE and MIQE guidelines, in reporting their work.
Additional material
Additional file 1: Supplementary Figures S1-S3. Figure S1: Examples
of transcript validation and analysis of the expression of Zic1, negatively
regulated by Pax3. (A, B) Examples of the analysis of transcripts in
different Pax3-GFP cell populations isolated from Pax3
GFP/+ embryos at
E10.5. (A) RT-PCR analysis of RNA extracted from FACs sorted GFP
positive and GFP negative cells from Pax3
GFP/+ embryos, as indicated in
Figure 1 showing that transcripts for the neural tube markers, Sox2 and
Sox10, which are potential Pax3 targets in neural crest, since the
transcripts are enriched in whole somite preparations which include
neural tissue. (B) RT-PCR analysis of transcripts in GFP positive cells from
the hypaxial versus whole somites of Pax3
GFP/+ embryos. c-Met, Six1, Sim1
and Zic1 transcripts are shown, with HPRT transcripts as a control. Zic1
expression is higher in the whole somite preparation, consistent with a
more epaxial location. (C) Immunohistochemistry with Zic1 and Pax3
antibodies on a transverse section of an interlimb somite of an E10.5
embryo, showing Zic1 protein mainly detected in Pax3 positive epithelial
cells of the epaxial dermomyotome (Ep), as well as in the dorsal neural
tube (NT) and in mesenchymal cells between the neural tube and
somites. Zic1 is mainly absent from Pax3 positive migratory neural crest
in this region. (D, E) Whole mount in situ hybridization with a Zic1 probe
on posterior somites of control Pax3
GFP/+ (D) and mutant Pax3
GFP/GFP (E)
embryos at E11, showing up-regulation in the absence of Pax3. Cell
death is extensive in the hypaxial domain of more anterior somites by
this stage, but despite some loss of cells in immature posterior somites,
Zic1 hybridisation is still higher in the Pax3 mutant. (F, G) Transverse
sections of immature posterior somites from Pax3
GFP/+ (F) and Pax3
GFP/GFP
(G) embryos at E11. In this tail region, immature somites have not yet
undergone cell death. In the control (F), transcripts are concentrated in
the more central and epaxial domain whereas in the Pax3 mutant (G)
they are detected throughout the somite. NT, neural tube. Figure S2: The
onset of myogenesis in Sprouty1 mutants and reduction of Sprouty2
expression in the absence of Pax3. (A-D) Whole mount in situ
hybridisation on Sprouty1
lacZ/+ (A, C) and Sprouty1
lacZ/- (B, D) embryos at
E10 (somite stages (ss) are indicated), using Myf5 (A, B) and MyoD (C, D)
probes. FL, forelimb bud. (E, F) In situ hybridisation with a Sprouty2 probe
on E9.5 (E), and with a Sprouty4 probe on E10.5 (F), embryos showing
interlimb somites and limb buds. There is extensive Sprouty expression in
the distal limb buds, but positive Sprouty4 positive myogenic
progenitors in the proximal forelimb bud are detectable at E10.5 (arrow).
Figure S3: Expression of Gremlin1 and perturbation of MyoD activation in
Gremlin1 mutant embryos. (A, B, D-I) Whole mount in situ hybridisation
on wild type (A, B), control (PGK-Cre) (D, D’), Pax3
PAX3-FKHR/+ (E, E’),
Gremlin1
+/- (Grem1
+/-) (F, H) and Gremlin1
-/- (G, I) embryos at the stages
indicated (ss, somite stage), using Gremlin1 (Grem1) (A-E’), Myf5 (F, G) and
MyoD (H, I) probes. (C) Transverse section of the embryo shown in (B) at
the level indicated by the white bar in (B). Note the expression of Grem1
in the hypaxial domain of the dermomyotome (Hyp). NT, neural tube;
DA, dorsal aorta; FL, forelimb bud; HL, hindlimb bud. Arrows and
arrowheads point to differences in expression in forelimb buds and more
posterior somites, respectively.
Additional file 2: Tables S1-S3. In all tables, the probe name
corresponds to the probe set designed by Affymetrix. In some cases,
multiple probe sets correspond to the same transcript, the name of
which is indicated in the gene title and gene symbol columns. When a
probe set has not yet been annotated, a - sign has been assigned or the
corresponding Riken number. The Fold change (FC) corresponds to the
difference in signal intensities between Pax3
PAX3-FKHR/GFP and Pax3
GFP/+
embryos. This number is not on a logarithmic scale. The Adjusted (Adj)
p-Value is also indicated. Table S1: Transcripts up-regulated (Table 1S-A)
or down-regulated (Table 1S-B) in Pax3
PAX3-FKHR/GFP (in comparison with
Pax3
GFP/+ embryos) in both forelimb and somite extracts. Table S2:
Transcripts up-regulated (Table S2-A) or down-regulated (Table S2-B) in
Pax3
PAX3-FKHR/GFP (in comparison with Pax3
GFP/+ samples) in forelimb buds.
Table S3: Transcripts up-regulated (Table S3-A) or down-regulated (Table
S3-B) in Pax3
PAX3-FKHR/GFP (in comparison with Pax3
GFP/+ samples) in
somites.
Additional file 3: Table S4. Transcripts that are specifically expressed in
GFP positive muscle progenitor cells and that are not detected in the
GFP negative population of the forelimb bud. This list of transcripts
corresponds to myogenic progenitor cell markers. In this table, mean
intensity, not fold change ((shown in Tables S1-3), is represented.
Additional file 4: Table S5. Sequence of reverse (Rev) and forward
(Fwd) primers used for semi-quantitative and quantitative PCR.
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